77.8% a high success rate: LNJP Director on Covaxin’s efficacy in phase 3 trials
- 3 years ago
Lok Nayak Jai Prakash Narayan (LNJP) Hospital Medical Director Dr Suresh Kumar expressed confidence on Bharat Biotech’s Covid-19 vaccine’s (Covaxin) efficacy rate in phase 3 of clinical trials. “It’s a very good result of the efficiency data of phase 3 clinical trial. 77.8 per cent is very high success rate and again it is a world class vaccine. We welcome these results,” said Dr Suresh Kumar.